Esomeprazole Pathway


Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, Esomeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Pathway legend Zoom in Zoom out

Pathway Image

Pathway legend Zoom in Zoom out

References

  1. DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G, & Posey, M.L. (2005). Pharmacotherapy: A pathologic approach. (6 th ed) pp.621-623. New York: McGraw-Hill Medical Publishing Division.
  2. Horn, J. (2000). The proton-pump inhibitors: Similarities and differences. Clinical Therapeutics, 22(3), 266-280. PMID: 10963283
  3. Nexium. (2009). [Electronic version]. e-CPS. Retrieved July 1, 2009.